Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Champions Oncolog (CSBR)

Champions Oncolog (CSBR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,532
  • Shares Outstanding, K 13,594
  • Annual Sales, $ 50,160 K
  • Annual Income, $ -7,280 K
  • 60-Month Beta 0.46
  • Price/Sales 1.36
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CSBR with:

Options Overview Details

View History
  • Implied Volatility 150.27% ( +108.90%)
  • Historical Volatility 71.04%
  • IV Percentile 78%
  • IV Rank 33.57%
  • IV High 434.43% on 08/29/24
  • IV Low 6.69% on 12/27/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 3.38
  • Today's Open Interest 302
  • Open Int (30-Day) 163

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +525,889.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.60 +32.50%
on 09/10/24
5.45 -12.48%
on 09/16/24
+0.28 (+6.24%)
since 08/16/24
3-Month
3.60 +32.50%
on 09/10/24
5.45 -12.48%
on 09/16/24
-0.14 (-2.85%)
since 06/18/24
52-Week
3.60 +32.50%
on 09/10/24
7.13 -33.10%
on 01/17/24
-0.43 (-8.27%)
since 09/18/23

Most Recent Stories

More News
Stocks Rise Before the Open as Investors Await Key U.S. PPI Data, ECB Decision in Focus

September S&P 500 E-Mini futures (ESU24) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.27% this morning as investors braced for crucial U.S. producer inflation data while also...

ESU24 : 5,635.25 (-0.07%)
NQU24 : 19,410.00 (-0.15%)
FSLR : 245.44 (+2.28%)
ENPH : 121.92 (+2.86%)
ARM : 140.34 (+2.56%)
NVDA : 115.35 (-0.21%)
ALB : 86.95 (-3.20%)
GME : 19.75 (-2.03%)
ADBE : 509.43 (-1.09%)
ROG.Z.IX : 268.200 (+0.83%)
OXM : 86.46 (+1.10%)
CSBR : 4.65 (+1.09%)
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its...

CSBR : 4.65 (+1.09%)
Champions Oncology Reports Quarterly Revenue of $12.9 Million

Record Annual Revenue of $49.1 Million

CSBR : 4.65 (+1.09%)
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.65 (+1.09%)
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven...

CSBR : 4.65 (+1.09%)
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

CSBR : 4.65 (+1.09%)
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.65 (+1.09%)
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.65 (+1.09%)
Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors

HACKENSACK, NJ / ACCESSWIRE / February 15, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.65 (+1.09%)
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates

HACKENSACK, NJ / ACCESSWIRE / January 20, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.65 (+1.09%)

Business Summary

Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the...

See More

Key Turning Points

3rd Resistance Point 5.46
2nd Resistance Point 5.29
1st Resistance Point 4.94
Last Price 4.65
1st Support Level 4.43
2nd Support Level 4.26
3rd Support Level 3.91

See More

52-Week High 7.13
Fibonacci 61.8% 5.78
Fibonacci 50% 5.37
Fibonacci 38.2% 4.95
Last Price 4.65
52-Week Low 3.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar